All In Biotech

Investigational drug · Phase 3

for organ preservation in transplantation

Also called: Custodiol-N, Custodiol

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Heart Transplantation, Kidney Failure, Liver Failure, Chronic.

Phase 3

Last checked: Nov 20, 2026Latest source record: Jan 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

8

Any phase or sponsor naming "for organ preservation in transplantation"

First trial start

2019

May 23, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "for organ preservation in transplantation", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Heart Transplantation
  • Kidney Failure
  • Liver Failure, Chronic
  • Kidney-Pancreas Failure

Approved drugs for the same conditions: Cardiovascular and metabolic · Kidney and urology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "for organ preservation in transplantation" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 249 on PubMed

Also in development for Heart Transplantation

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.